Regular Article

British Journal of Cancer (2000) 82, 34–38. doi:10.1054/bjoc.1999.0873 www.bjcancer.com
Published online 10 December 1999

Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells

S Isonishi1, K Ohkawa2, T Tanaka1 and S B Howell3

  1. 1Departments of Obstetrics/Gynecology Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, 105, Japan
  2. 2Biochemistry, Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, 105, Japan
  3. 3The Cancer Center, University of California, San Diego, La Jolla, 92093, USA

Received 9 February 1999; Revised 21 June 1999; Accepted 16 July 1999.

Top

Abstract

Down-regulation of protein kinase C (PKC) by 12- O -tetradecanoylphorbol-13-acetate (TPA) enhances the sensitivity of human ovarian carcinoma 2008 cells to various types of platinum compounds such as cisplatin (DDP), carboplatin and (–)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)-platinum(II) monohydrate (DWA) by a factor of two- to threefold. TPA enhanced the sensitivity of the DDP-resistant 2008/C13*5.25 subline to each of these three drugs to the same extent as for the 2008 cells. The extent of PKC down-regulation and drug sensitization depended on the duration of TPA exposure; maximum effect was achieved with a 48 h pretreatment. Sensitization was TPA concentration-dependent and was maximal at 0.05 muM TPA. 2008 cells expressed only the PKCalpha and PKCzeta isoforms. Western blot analysis revealed that whereas the expression of PKCalpha was reduced by TPA the level of PKCzeta was not affected. These results suggest that PKCalpha is the isotype responsive to TPA in these cells and that platinum drug sensitivity can be modulated by this isoform alone. In parallel to its effect on PKCalpha, TPA decreased cellular glutathione content by 30 plusminus 3 (standard deviation (s.d.) % in 2008 cells and by 41 plusminus 3 (s.d.) % in 2008/C13*5.25 cells. TPA also increased accumulation of DDP and DWA by 70%, although this effect was limited to the 2008/C13*5.25 cells. TPA rendered 2008 and 2008/C13*5.25 cells resistant to cadmium chloride by a factor of 3.7 and 3.6-fold respectively, suggesting a significant increase in cellular metallothionein content. Although the mechanism of TPA induced sensitization is not yet fully understood, this study points to a central role for PKCalpha in modulating platinum drug sensitivity. © 2000 Cancer Research Campaign

Keywords:

platinum agents, protein kinase C, drug sensitivity

Top

References

  1. Andrews PA and Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35–43 | PubMed | ISI | ChemPort |
  2. Andrews PA, Murphy MP and Howell SB (1985) Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 45: 6250–6253 | PubMed | ISI | ChemPort |
  3. Balboa MA, Firestein BL, Godson C, Bell KS and Insel PA (1994) Protein kinase C alpha mediates phospholipase D activation by nucleotides and phorbol ester in Madin-Darby canine kidney cells. Stimulation of phospholipase D is independent of activation of polyphosphoinositide-specific phospholipase C and phospholipase A2. J Biol Chem 269: 10511–10516 | PubMed | ISI | ChemPort |
  4. Basu A, Teicher BA and Lazo JS (1990) Involvement of protein kinase C in phorbor ester-induced sensitization of Hela cells to cis-diamminedichloroplatinum(II). J Biol Chem 265: 8451–8457 | PubMed |
  5. Blagosklonny MV, Prabhu NS and El-Deiry WS (1997) Defects in P21WAF1/CIP1, Rb, and c-myc signaling in phorbol-resistant cancer cells. Cancer Res 57: 320–325 | PubMed | ISI | ChemPort |
  6. Brach MA, Herrmann F and Kufe DW (1992) Activation of the AP-1 transcription factor by arabinofuranosylcytosine in myeloid leukemia cells. Blood 79: 728–734 | PubMed | ISI | ChemPort |
  7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principal of protein-dye binding. Anal Biochem 72: 248–254 | Article | PubMed | ISI | ChemPort |
  8. Bruder JT, Heidecker G and Rupp UR (1992) Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes and Dev 6: 545–556
  9. Chambers TC, McAvoy EM, Jacobs JW and Eilon G (1990) Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 265: 7679–7687 | PubMed |
  10. Chmura SJ, Nodzenski E, Weichselbaum II RR and Quintans J (1966) Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinasel. Cancer Res 56: 2711–2714
  11. Craven PA and DeRubertis D (1988) Role of activation of protein kinase C in the stimulation of colonic epithelial proliferation by unsatulated fatty acids. Gastroenterology 95: 676–685
  12. Disaida PJ, Sinkovics JG, Rutledge FN and Smith JP (1972) Cell-mediated immunity to human malignant cells. Am J Obstet Gynecol 114: 979–989 | PubMed | ChemPort |
  13. Fine RL, Patel J and Chabner BA (1988) Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85: 582–586
  14. Fung H, Quinlan TR, Janssen YMW, Timblin CR, Marsh JP, Heintz NH, Taatjes DJ, Vacek P, Jaken S and MossmanII BT (1997) Inhibition of protein kinase C prevents asbestos-induced c-fos and c-jun proto-oncogene expression in mesothelial cells. Cancer Res 57: 3101–3105
  15. Gately DP and Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171–1176 | PubMed | ISI | ChemPort |
  16. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC and Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci 89: 3070–3074
  17. Hsu SL, Chou YH, Yin SC and Liu JY (1998) Differential effects of phorbol ester on growth and protein kinase C isoenzyme regulation in human hepatoma Hep3B cells. Biochem J 33: 57–64
  18. Isonishi S, Andrews PA and Howell SB (1990) Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12- O -tetradecanoylphorbol 13-acetate. J Biol Chem 265: 3623–3627 | PubMed |
  19. Isonishi S, Hom DK, Eastman A and Howell SB (1994 a) Enhancement of sensitivity to platinum(II)-containing drugs by 12- O -tetradecanoylphorbol-13-acetate in a human ovarian carcinoma cell line. Br J Cancer 69: 217–221 | PubMed |
  20. Isonishi S, Ochiai K, Yasuda M, Ohkawa K and Terashima Y (1994 b) Mechanism-related circumvention of cisplatin resistance in human ovarian carcinoma cells by (–)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)-platinum(II) monohydrate and modulation of its sensitivity by 12- O -tetradecanoylphorbol-13-acetate. Int J Oncol 5: 1309–1314
  21. Kelly SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lzo JS (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813–1815 | PubMed |
  22. Kolch W, Heldecker G, Kochs G, Hummel R, Vahida H, Mischak H, Finkenzeller G, Marmé D and Rapp UR (1993) Protein kinase Calpha activates raf-1 by direct phosphorylation. Nature 364: 249–252 | Article | PubMed | ISI | ChemPort |
  23. Kondo Y, Woo ES, Michalska AE, Andy Choo KH and Lazo J (1995) Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res 55: 2021–2023 | PubMed |
  24. Loehrer PJ and Einhorn LH (1984) Cisplatin. Ann Inter Med 100: 704–713
  25. McCaffrey R, Ran W, Camisi J and Rosner MR (1987) Two independent growth factor-generated signals regulate c-fos and c-myc mRNA levels in Swiss 3T3 cells. J Biol Chem 262: 1442–1445
  26. Niedel JE, Kuhn LJ and Vandenbark GR (1983) Phorbol diester receptor copurifies with protein kinase C. Proc Natl Acad Sci USA 80: 36–40 | Article | PubMed | ChemPort |
  27. Ozols RF and Young RC (1984) Chemotherapy of ovarian cancer. Semin Oncol 11: 251–263 | PubMed | ChemPort |
  28. Rahmsdorf HJ and Herrlich P (1990) Regulation of gene expression by tumor promotors. Pharmacol Ther 48: 157–188
  29. Rapp UR (1991) Role of raf-1 serine/threonine protein kinase in growth factor signal transduction. Oncogene 6: 495–500 | PubMed | ChemPort |
  30. Reed DJ, Babson JR, Beatty PW, Brodie AE, Ellis WW and Potter DW (1980) High-performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulfide, and related thiols and disulfides. Anal Biochem 106: 55–62 | Article | PubMed | ISI | ChemPort |
  31. Schilder RJ and Ozols RF (1992) New therapies for ovarian cancer. Cancer Invest 10: 307–315 | PubMed |
  32. Smeal T, Binetruy B, Mercola D, Grover-Bardwick A, Heidecker G, Rapp UR and Karin M (1992) Oncoprotein-mediated signalling cascade stimulates C-Jun activity by phosphorylation of serines 63 and 73. Mol Cell Biol 12: 3507–3513 | PubMed | ISI | ChemPort |